Posted in M&A / Deals Neurocrine to acquire Prader-Will drug in $2.9B Soleno buyout April 6, 2026 BioPharma Dive The deal hands Neurocrine a controversial medicine, Vykat, that achieved $190 million in sales last year but faces persistent questions about its growth trajectory and safety, according to Wall Street M&A / DealsRare DiseaseRead full story